HLN 6-K
Haleon plc (HLN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2024
Commission File Number: 001-41411
Haleon plc
(Translation of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form<br>20-F ☒ | Form<br>40-F ☐ |
|---|
EXHIBIT INDEX
| Exhibit<br>Number | Description |
|---|---|
| 99.1 | 19<br>December 2024 - “Director/PDMR<br>Shareholding” |
99.1
Haleon plc: Director/PDMR Shareholding
19 December 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
| 1 | Details of the person discharging managerial responsibilities /<br>person closely associated | ||
|---|---|---|---|
| a) | Name | Adrian<br>Morris | |
| 2 | Reason for the notification | ||
| a) | Position/status | General<br>Counsel - PDMR | |
| b) | Initial<br>notification /Amendment | Initial<br>Notification | |
| 3 | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction<br>monitor | ||
| a) | Name | Haleon<br>plc | |
| b) | LEI | 549300PSB3WWEODCUP19 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transactions have been<br>conducted | ||
| a) | Description<br>of the financial instrument, type of<br>instrument | Ordinary<br>Shares of 0.01 each | |
| Identification<br>code | GB00BMX86B70 | ||
| b) | Nature<br>of the transaction | Grant<br>of a 3-year option over Ordinary Shares under the 2024 Haleon Share<br>Save Plan which will first become exercisable 1 February<br>2028. | |
| c) | Price(s)<br>and volume(s) | ||
| Volume(s) | |||
| 6,150 | |||
| d) | Aggregated<br>information | ||
| -<br>Aggregated volume | |||
| -<br>Price | |||
| e) | Date of<br>the transaction | 19<br>December 2024 | |
| f) | Place<br>of the transaction | Outside<br>a trading venue |
All values are in British Pounds.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HALEON PLC<br><br><br>(Registrant) | |||
|---|---|---|---|
| Date: December 19,<br>2024 | By: | /s/<br>Amanda Mellor | |
| Name: | Amanda<br>Mellor | ||
| Title: | Company<br>Secretary |